adamantylamide-alanyl-isoglutamine has been researched along with Disease, Pulmonary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Becker, PD; Bertot, GM; Grinstein, S; Guzmán, CA | 1 |
| Aranibar Urey, RC; Bertot, GM; Galanternik, L; Grinstein, S; Restelli, MA; Valvano, MA | 1 |
2 other study(ies) available for adamantylamide-alanyl-isoglutamine and Disease, Pulmonary
| Article | Year |
|---|---|
Intranasal vaccination with recombinant P6 protein and adamantylamide dipeptide as mucosal adjuvant confers efficient protection against otitis media and lung infection by nontypeable Haemophilus influenzae.
Topics: Adjuvants, Immunologic; Administration, Intranasal; Amantadine; Animals; Antibodies, Bacterial; Bacterial Outer Membrane Proteins; Bronchoalveolar Lavage Fluid; Dipeptides; Female; Haemophilus Infections; Haemophilus influenzae; Haemophilus Vaccines; Immunization; Lung Diseases; Mice; Mice, Inbred BALB C; Otitis Media; Recombinant Proteins; Saliva; Vagina | 2004 |
Nasal immunization with Burkholderia multivorans outer membrane proteins and the mucosal adjuvant adamantylamide dipeptide confers efficient protection against experimental lung infections with B. multivorans and B. cenocepacia.
Topics: Adjuvants, Immunologic; Administration, Intranasal; Amantadine; Animals; Antibodies, Bacterial; Bacterial Outer Membrane Proteins; Burkholderia cepacia complex; Burkholderia Infections; Dipeptides; Disease Models, Animal; Immunization; Lung Diseases; Mice; Mice, Inbred BALB C | 2007 |